Primary myelofibrosis (PMF) or myelofibrosis secondary to polycythemia vera (PV-MF) or
essential thrombocythemia (ET-MF) can be cured only by means of allogeneic …

Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) constitutes the only
curative treatment for myelofibrosis (MF), but its associated toxicity remains high. Prognostic …

The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …

Objective Little information is available about the outcome of allogeneic hematopoietic stem
cell transplantation (HSCT) for patients with secondary myelofibrosis from essential …

Abstract 1019 Allogeneic stem cell transplantation is the only curative treatment for
myelofibrosis. Here we present a long–term follow up of patients with myelofibrosis treated …

Primary or post-ET/PV myelofibrosis is one of the Philadelphia-negative myeloproliferative
neoplasms with worst survival. Allogeneic stem cell transplantation (ASCT) can cure a …

Background Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by
allogeneic hematopoietic stem cell transplantation and is associated with substantial …

Primary myelofibrosis (PMF) is a chronic myeloid malignancy characterized by stem cell-
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …

Myelofibrosis (MF) is a rare disease responsible for an increasing ineffective hematopoesis
by a progressive fibrosing process in the bone marrow. The only curative treatment option is …

Though medical therapy is used in patients with symptomatic primary myelofibrosis (MF) to
correct cytopenias and halt the progression of splenomegaly, it does not alter the natural …